{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:34:26Z","timestamp":1767591266078,"version":"3.48.0"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Carcinoma of unknown primary (CUP) is typically associated with a poor prognosis, with a median survival of less than one year. This article reports a rare case of an alpha-fetoprotein (AFP)-positive CUP patient who achieved a long-term survival of nearly five years, whose diagnostic and therapeutic course offers significant clinical insights.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 67-year-old male patient presented with left neck lymphadenopathy. A comprehensive workup revealed no primary site, leading to a diagnosis of CUP. Although subsequent immunohistochemistry classified the case into the unfavorable prognostic subgroup, an individualized treatment strategy including three-drug combination chemotherapy based on the clinical suspicion of gastric cancer, targeted therapy with Apatinib, and localized radiotherapy, resulted in a remarkably long overall survival of 58 months. Serum AFP levels closely correlated with disease activity throughout the clinical course.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This case demonstrates that for CUP confined to lymph nodes, active and precisely reasoned individualized treatment can significantly improve prognosis, even in cases categorized as having an unfavorable prognosis. Furthermore, it underscores the necessity of immunohistochemistry for the accurate diagnosis of CUP and suggests that promoting precision medicine strategies may improve outcomes for these patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2025.1724466","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:24Z","timestamp":1767590964000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A case of lymph node metastatic cancer of unknown primary with elevated alpha-fetoprotein achieving long-term survival"],"prefix":"10.3389","volume":"15","author":[{"given":"Yan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Qun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bi-Fei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.97","article-title":"Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary","volume":"14","author":"Moran","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2014.03.010","article-title":"Descriptive epidemiology of cancer of unknown primary site in scotland, 1961-2010","volume":"38","author":"Brewster","year":"2014","journal-title":"Cancer Epidemiol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6601085","article-title":"Summary of the standards, options and recommendations for the management of patients with carcinoma of unknown primary site (2002)","author":"Bugat","year":"2003","journal-title":"Br J Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr536","article-title":"Survival in cancer of unknown primary site: population-based analysis by site and histology","volume":"23","author":"Hemminki","year":"2012","journal-title":"Ann Oncol Off J Eur Soc Med Oncology\/ESMO"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.102882","article-title":"New rising entities in cancer of unknown primary: is there a real therapeutic benefit","volume":"147","author":"Rassy","year":"2020","journal-title":"Crit Rev oncology\/hematology"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0959-8049(01)00378-1","article-title":"Epidemiology of unknown primary tumours; incidence and population-based survival of 1285 patients in southeast Netherlands, 1984-1992","volume":"38","author":"van de Wouw","year":"2002","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.1689","article-title":"Cancer of unknown primary-epidemiological trends and relevance of comprehensive genomic profiling","volume":"7","author":"Binder","year":"2018","journal-title":"Cancer Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103208","article-title":"Melanoma of unknown primary: new perspectives for an old story","volume":"158","author":"Boussios","year":"2021","journal-title":"Crit Rev oncology\/hematology"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.11.013","article-title":"Cancer of unknown primary: esmo clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Kramer","year":"2023","journal-title":"Ann Oncol Off J Eur Soc Med Oncology\/ESMO"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2022.06.017","article-title":"Chromosomal instability in cancers of unknown primary","volume":"172","author":"Chebly","year":"2022","journal-title":"Eur J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s43046-022-00128-1","article-title":"Sarcoma of unknown primary: myth or reality","volume":"34","author":"Rassy","year":"2022","journal-title":"J Egyptian Natl Cancer Institute"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103662","article-title":"Unfavorable carcinoma of unknown primary with a gastrointestinal profile: A retrospective study","volume":"9","author":"Guidi","year":"2024","journal-title":"ESMO Open"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-3766.2017.11.001","article-title":"Afp-producing gastric cancer and hepatoid gastric cancer","volume":"39","author":"Wang","year":"2017","journal-title":"Zhonghua zhong liu za zhi [Chinese J oncology]"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.635537","article-title":"The clinicopathological characteristics of alpha-fetoprotein-producing adenocarcinoma of the gastrointestinal tract-a single-center retrospective study","volume":"11","author":"Kong","year":"2021","journal-title":"Front Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1487334","article-title":"Long term survival\u00a0of\u00a0advanced hepatoid adenocarcinoma of lung secondary to idiopathic pulmonary fibrosis: A case report","volume":"15","author":"Wang","year":"2025","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i2.266","article-title":"Predictive and prognostic value of serum afp level and its dynamic changes in advanced gastric cancer patients with elevated serum afp","volume":"24","author":"Wang","year":"2018","journal-title":"World J Gastroenterol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e13583","DOI":"10.1111\/eci.13583","article-title":"Genomic correlates of response and resistance to immune checkpoint inhibitors in carcinomas of unknown primary","volume":"51","author":"Rassy","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2013.0070","article-title":"Gastric cancer, version 2.2013: featured updates to the nccn guidelines","volume":"11","author":"Ajani","year":"2013","journal-title":"J Natl Compr Cancer Network: JNCCN"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.101004","article-title":"Efficacy and safety of apatinib for the treatment of afp-producing gastric cancer","volume":"14","author":"Li","year":"2021","journal-title":"Trans Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.48.8585","article-title":"Apatinib for chemotherapy-refractory advanced metastatic gastric cancer: results from a randomized, placebo-controlled, parallel-arm, phase ii trial","volume":"31","author":"Li","year":"2013","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2014.216","article-title":"Comprehensive genomic profiling of carcinoma of unknown primary site: new routes to targeted therapies","volume":"1","author":"Ross","year":"2015","journal-title":"JAMA Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00313-9","article-title":"Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan cup-001): A randomised controlled trial","volume":"25","author":"Liu","year":"2024","journal-title":"Lancet Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00814-6","article-title":"Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (Cupisco): an open-label, randomised, phase 2 study","volume":"404","author":"Kramer","year":"2024","journal-title":"Lancet"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102407","article-title":"Systematic review of the cup trials characteristics and perspectives for next-generation studies","volume":"107","author":"Rassy","year":"2022","journal-title":"Cancer Treat Rev"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1724466\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T05:29:29Z","timestamp":1767590969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1724466\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":24,"alternative-id":["10.3389\/fonc.2025.1724466"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1724466","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]},"article-number":"1724466"}}